# Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer

> **NCT00017303** · PHASE2 · UNKNOWN · sponsor: **Cytran**

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** oglufanide disodium
- **DRUG:** paclitaxel
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00017303
- **Lead sponsor:** Cytran
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017303, "Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00017303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*